Testing Objective Methods for Template Matching Ventricular Tachycardia and Pacemapping
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01170416 |
Recruitment Status
:
Completed
First Posted
: July 27, 2010
Last Update Posted
: May 17, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Ventricular Tachycardia | Other: 12-lead body surface mapping |

Study Type : | Observational |
Actual Enrollment : | 20 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Quantitative Measurements Comparing Body Surface Potentials During Pacemapping and Spontaneous Ventricular Tachycardia |
Study Start Date : | July 2010 |
Actual Primary Completion Date : | July 2011 |
Actual Study Completion Date : | July 2011 |
Group/Cohort | Intervention/treatment |
---|---|
12-Lead Body Surface Mapping - Focal VT .
Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
|
Other: 12-lead body surface mapping
An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
|
12-Lead BSPM - Scar related VT, exit not identified
Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
|
Other: 12-lead body surface mapping
An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
|
12-Lead BSPM - Scar related VT exit identified
Body surface mapping will be competed on patients with scar related VT where the exit is identified
|
Other: 12-lead body surface mapping
An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
|
12-Lead BSPM - Supraventricular tachycardia
Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
|
Other: 12-lead body surface mapping
An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
|
- Correlating the arithmetic markers (CORR and MAD) to the distance between the pacing site and origin of the ventricular tachycardia or the index pacing site. [ Time Frame: One year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All patients presenting with sustained monomorphic VT who are amenable to VT ablation.
- Patients referred for ablation of supraventricular tachycardia.
Exclusion Criteria:
- Patients presenting with ventricular tachycardia if no sustained tachycardia can be induced, or if in that particular patient pace-mapping is known to be an inaccurate method of mapping (e.g. in bundle branch reentry VT or fascicular VT).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01170416
Canada, Nova Scotia | |
Capital District Health Authority | |
Halifax, Nova Scotia, Canada, B3H 3A7 |
Principal Investigator: | John A Sapp, MD, FRCPC | Nova Scotia Health Authority |
Publications:
Responsible Party: | John Sapp, Electrophysiologist, Nova Scotia Health Authority |
ClinicalTrials.gov Identifier: | NCT01170416 History of Changes |
Other Study ID Numbers: |
SP12 |
First Posted: | July 27, 2010 Key Record Dates |
Last Update Posted: | May 17, 2016 |
Last Verified: | May 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Keywords provided by John Sapp, Nova Scotia Health Authority:
Ventricular Tachycardia Body Surface Mapping |
Additional relevant MeSH terms:
Tachycardia Tachycardia, Ventricular Arrhythmias, Cardiac |
Heart Diseases Cardiovascular Diseases Pathologic Processes |